| Long name: |
ALEXA FLUOR 555 Conjugated, Apolipoprotein CII/APOC2 Antibody |
| Also known as: |
Anti-Apolipoprotein CII/APOC2 PAb ALEXA FLUOR 555 |
| Category: |
Conjugated Primary Antibodies |
| Conjugated with: |
555, ALEXA FLUOR® |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
Apolipoprotein CII/APOC2 |
| Specificity: |
This is a highly specific antibody against Apolipoprotein CII/APOC2 |
| Modification: |
Unmodified |
| Modification Site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human Apolipoprotein CII/APOC2 |
| Gene ID Number: |
344 |
| Tested applications: |
IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Human |
| Cross-reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the antigen: |
The apolipoprotein C gene family encodes four homologous proteins designated apoC-I to -IV, The human apoC-I gene maps to chromosome 19q13, The human apoC-II gene maps to chromosome 19q13, The human apoC-III gene maps to chromosome 11q23 and encodes a protein that may delay catabolism of triglyceride-rich particles by inhibiting lipoprotein lipase and hepatic lipase (8), The human apoC-IV gene maps to chromosome 19q13, the enzyme that hydrolyzes triglycerides in plasma and transfers the fatty acids to tissues (5â, which specifically modulate the metabolism of triglyceride-rich lipoproteins (2), &euro, &ldquo, 10), 2 and encodes a 127 amino acid protein that is primarily expressed in the liver (9, 2 and encodes a 79 amino acid single chain protein that is a necessary cofactor for the activation of lipoprotein lipase, 2 and is expressed primarily in the liver where it is activated when monocytes differentiate into macrophages (3, 4), 7), Apolipoproteins are protein components of plasma lipoproteins (1) |
| Purification: |
Purified by Protein A |
| Storage conditions: |
50% glycerol and 0, Keep refrigerated at 2 to 8 degrees Celcius for up to one year, 09% sodium azide, Store this antibody in aqueous buffered solution containing 1% BSA |
| Excitation emission: |
553nm/568nm |
| Synonyms: |
APC2, APOC 2, APOC2 protein, Apo CII, ApoC II, ApoCII, Apolipoprotein C II, Apolipoprotein C II precursor, ApolipoproteinCII, MGC75082, apoC-II , APC 2, APOC2 |
| Properties: |
ALEXA FLUOR they should be stored frozen at - 24°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies, Very high photo stable ALEXA conjugate, C, C for long term storage and for short term at + 5°, For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
ALEXA FLUOR 555, Alexa Fluor |
| Gene target: |
Apolipoprotein CII/APOC2 |
| Short name: |
Apolipoprotein CII/APOC2 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Label: |
ALEXA FLUOR 555 |
| Alternative name: |
ALEXA FLUOR 555, Apolipoprotein CII/apolipoprotein C-II (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
APO-CII and APOC-II, APOC2 and IDBG-306903 and ENSG00000234906 and 344, APOC2 and IDBG-639315 and ENSBTAG00000020558 and 618039, Apoc2 and IDBG-151996 and ENSMUSG00000002992 and 11813, Extracellular, lipoprotein lipase activator activity, this GO :0001523 and retinoid metabolic process and biological process this GO :0005576 and extracellular region and cellular component this GO :0005615 and extracellular space and cellular component this GO :0005769 and early endosome and cellular component this GO :0006629 and lipid metabolic process and biological process this GO :0006869 and lipid transport and biological process this GO :0007603 and phototransduction, this GO :0008047 : enzyme activator activity, this GO :0008047 : enzyme activator activity and also this GO :0008289 : lipid binding and also this GO :0016004 : phospholipase activator activity and also this GO :0042803 : protein homodimerization activity and also this GO :0043274 : phospholipase binding and also this GO :0055102 : lipase inhibitor activity and also this GO :0060230 : lipoprotein lipase activator activity, this GO :0008289 : lipid binding, this GO :0016004 : phospholipase activator activity, this GO :0042803 : protein homodimerization activity, this GO :0043274 : phospholipase binding, this GO :0055102 : lipase inhibitor activity, this GO :0060230 : lipoprotein lipase activator activity, visible light and biological process this GO :0008047 and enzyme activator activity and molecular function this GO :0008289 and lipid binding and molecular function this GO :0010518 and positive regulation of phospholipase activity and biological process this GO :0010898 and positive regulation of triglyceride catabolic process and biological process this GO :0010902 and positive regulation of very-low-density lipoprotein particle remodeling and biological process this GO :0010916 and negative regulation of very-low-density lipoprotein particle clearance and biological process this GO :0016004 and phospholipase activator activity and molecular function this GO :0016042 and lipid catabolic process and biological process this GO :0032375 and negative regulation of cholesterol transport and biological process this GO :0033344 and cholesterol efflux and biological process this GO :0033700 and phospholipid efflux and biological process this GO :0034361 and very-low-density lipoprotein particle and cellular component this GO :0034362 and low-density lipoprotein particle and cellular component this GO :0034363 and intermediate-density lipoprotein particle and cellular component this GO :0034366 and spherical high-density lipoprotein particle and cellular component this GO :0034370 and triglyceride-rich lipoprotein particle remodeling and biological process this GO :0034371 and chylomicron remodeling and biological process this GO :0034372 and very-low-density lipoprotein particle remodeling and biological process this GO :0034382 and chylomicron remnant clearance and biological process this GO :0034384 and high-density lipoprotein particle clearance and biological process this GO :0042157 and lipoprotein metabolic process and biological process this GO :0042627 and chylomicron and cellular component this GO :0042632 and cholesterol homeostasis and biological process this GO :0042803 and protein homodimerization activity and molecular function this GO :0043085 and positive regulation of catalytic activity and biological process this GO :0043086 and negative regulation of catalytic activity and biological process this GO :0043274 and phospholipase binding and molecular function this GO :0043691 and reverse cholesterol transport and biological process this GO :0044281 and small molecule metabolic process and biological process this GO :0045723 and positive regulation of fatty acid biosynthetic process and biological process this GO :0045833 and negative regulation of lipid metabolic process and biological process this GO :0048261 and negative regulation of receptor-mediated endocytosis and biological process this GO :0051006 and positive regulation of lipoprotein lipase activity and biological process this GO :0055102 and lipase inhibitor activity and molecular function this GO :0060230 and lipoprotein lipase activator activity and molecular function this GO :0060697 and positive regulation of phospholipid catabolic process and biological process this GO :0070062 and extracellular vesicular exosome and cellular component this GO :0070328 and triglyceride homeostasis and biological process, apolipoprotein C-II |